Prenetics Global Limited - Class A Ordinary Share (PRE)
13.08
-3.68 (-21.96%)
NASDAQ · Last Trade: Oct 27th, 6:22 PM EDT
Detailed Quote
Previous Close
16.76
Open
13.97
Bid
13.04
Ask
13.50
Day's Range
12.42 - 14.42
52 Week Range
3.095 - 17.99
Volume
817,529
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
126,843
Chart
About Prenetics Global Limited - Class A Ordinary Share (PRE)
Prenetics Global Limited is a biotechnology company that specializes in providing advanced genetic testing and health insights. Through its innovative platform, the company offers a range of diagnostic solutions that empower individuals and healthcare professionals to make informed decisions regarding genetic health, chronic disease risk, and personalized medical care. Prenetics aims to enhance preventive healthcare by making genetic testing accessible and actionable, leveraging cutting-edge technology and data analytics to support wellness and disease management for its users. Read More
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Distinguished Investor Group Includes Kraken, American Ventures, Exodus (NYSE: EXOD), XtalPi (2228.hk), DL Holdings (1709.hk) GPTX by Jihan Wu and Leading Institutions
CHARLOTTE, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced the successful pricing of a best efforts public offering (the “Offering”) of (i) 2,992,596 Class A ordinary shares, par value $0.0015 per share, of the Company (the “Ordinary Shares,” the Ordinary Shares being sold in the Offering, the “Shares”) (or pre-funded warrants of the Company to purchase Ordinary Shares (the “Pre-funded Warrants”) in lieu thereof), (ii) warrants of the Company to purchase up to 2,992,596 Ordinary Shares (the “Class A Common Warrants”), and (iii) warrants of the Company to purchase up to 2,992,596 Ordinary Shares (the “Class B Common Warrants” and together with the Class A Common Warrants, the “Common Warrants”) at a combined offering price of $16.08 per Share (or Pre-funded Warrant) and the associated Common Warrants (the “Offering Price”). The gross proceeds to the Company from the offering are expected to be approximately $48.0 million, before deducting placement agent fees and offering expenses.
CHARLOTTE, N.C., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (“Prenetics” or the “Company”), a leading health sciences company, today announced that it has commenced a public offering of shares of its Class A Ordinary Shares (or prefunded warrants in lieu thereof) and common warrants (the “Offering”). The Company will allocate proceeds from the offering toward the global expansion of IM8, driven by its explosive growth, and the strategic accumulation of Bitcoin (BTC) as part of its pioneering dual-pronged health and wealth strategy.
CHARLOTTE, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading consumer health sciences company, today announced the official completion of its divestment of ACT Genomics Co., Ltd. (“ACT”) to Delta Electronics, Inc. (TWSE:2308). This transaction marks a final step in Prenetics’ strategic exit from the clinical diagnostics sector, enabling the company to dedicate its resources and attention to its rapidly expanding consumer health initiatives.
CHARLOTTE, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading health sciences company, and its premium supplement brand IM8, co-founded by David Beckham, today extends heartfelt congratulations to global ambassador and shareholder, World No. 1 tennis player Aryna Sabalenka, on successfully defending her singles championship at the 2025 US Open.
CHARLOTTE, N.C., June 26, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading consumer health sciences company, announced today at a special event at Wimbledon House that IM8, its premium supplements brand co-founded by David Beckham, has partnered with world No. 1 tennis star Aryna Sabalenka as its newest global ambassador and shareholder. The announcement comes just days before the start of Wimbledon on June 30th, where Sabalenka will be competing as one of the tournament favorites.
CHARLOTTE, N.C., June 18, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics”), a leading consumer health sciences company, today announced it has entered into a definitive agreement to divest its ownership in ACT Genomics Holdings Company Limited (“ACT Genomics”) to Delta Electronics, Inc. (TWSE: 2308) (“Delta”). Delta is a global leader in power management and smart green solutions, as well as a provider of healthcare technologies. The transaction regarding Delta’s acquisition of up to 100% ACT Genomics’ shareholdings is valued at up to US$71.78 million. Prenetics, holding a majority stake in ACT Genomics, will receive a gross proceed of approximately US$46 million in cash post-closing of the transaction and subject to customary release conditions. With a cash balance of US$44 million1, this divestment bolsters Prenetics financial position, increasing its pro-forma cash reserves to approximately US$86 million2 and with $117 million pro-forma short term assets3, while maintaining a debt-free balance sheet.
CHARLOTTE, N.C., June 12, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced unaudited financial results for the first quarter ended March 31, 2025, along with recent business updates.
David Beckham was Joined by Dr. Amy Shah, Dr. Jeremy London, Dr. James DiNicolantonio and Kendal Toole to Reinforce IM8’s Vision for Elite Wellness Accessible to All
CHARLOTTE, N.C., March 11, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading consumer health sciences company, announced today the Company will participate in the 37th Annual ROTH Conference being held Sunday, March 16th to Tuesday, March 18th at the Laguna Cliffs Marriott Resort in Dana Point, CA.
